MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAIA MAIA Biotechnology Inc.

Post-Mkt 04-29 17:41:07 EDT

1.30

+0.05

+4.00%

盘后1.34

+0.04+3.07%

17:20 EDT

High1.43	Low1.28	Vol1.19M
Open1.28	D1 Closing1.25	Amplitude12.00%
Mkt Cap78.87M	Tradable Cap72.31M	Total Shares60.67M
T/O1.58M	T/O Rate2.14%	Tradable Shares55.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAIA","market":"US","secType":"STK","nameCN":"MAIA Biotechnology Inc.","latestPrice":1.3,"timestamp":1777492800000,"preClose":1.25,"halted":0,"volume":1188675,"hourTrading":{"tag":"盘后","latestPrice":1.3399,"preClose":1.3,"latestTime":"17:20 EDT","volume":1942,"amount":2586.138096,"timestamp":1777497623574,"change":0.0399,"changeRate":0.030692,"amplitude":0.030769},"delay":0,"changeRate":0.040000000000000036,"floatShares":55623100,"shares":60671491,"eps":-0.7,"marketStatus":"Post-Mkt","change":0.05,"latestTime":"04-29 17:41:07 EDT","open":1.28,"high":1.43,"low":1.28,"amount":1579533.2116200002,"amplitude":0.12,"askPrice":1.38,"askSize":22,"bidPrice":1.29,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.7,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777507200000},"marketStatusCode":4,"adr":0,"listingDate":1659067200000,"exchange":"AMEX","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.3296,"preClose":1.25,"latestTime":"09:29 EDT","volume":27021,"amount":35355.5950248,"timestamp":1777469369317,"change":0.0796,"changeRate":0.06368,"amplitude":0.048},"postHourTrading":{"tag":"盘后","latestPrice":1.3399,"preClose":1.3,"latestTime":"17:20 EDT","volume":1942,"amount":2586.138096,"timestamp":1777497623574,"change":0.0399,"changeRate":0.030692,"amplitude":0.030769},"volumeRatio":2.585451},"requestUrl":"/m/hq/s/MAIA/tweets","defaultTab":"tweets","newsList":[{"id":"2627150952","title":"Maia Biotech opens first US site for Phase 2 THIO-101 lung cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627150952","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627150952?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:24","pubTimestamp":1776345889,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology activated first U.S. clinical site for its Phase 2 THIO-101 expansion trial testing ateganosine as third-line treatment for advanced non-small cell lung cancer.Trial expansion follows results already presented in 2025 that indicated outcomes above standard-of-care expectations in heavily pre-treated patients, including signs of durable benefit.Study is evaluating ateganosine alone or sequenced with Regeneron’s checkpoint inhibitor cemiplimab in patients who previously failed chemotherapy or checkpoint inhibitors.U.S. third-line evaluation is supported by an NIH grant of USD 2.3 million, positioning MAIA to broaden enrollment from its existing Europe and Asia footprint.Program holds FDA Fast Track designation, which could speed regulatory review if subsequent data support an accelerated pathway.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL5jsbXL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0882574055.USD","MAIA","LU0889565916.HKD","LU1917777945.USD","LU0823434740.USD","LU2362540622.SGD","LU2089984988.USD","LU2362541513.USD","REGN","LU1974910355.USD","LU0823416689.USD","LU0320765992.SGD","LU0058720904.USD","LU0114720955.EUR","LU2237438978.USD","LU2468319806.SGD","LU2362541273.HKD","LU0109394709.USD","LU0289739699.SGD","LU2023250504.SGD","BK4588","BK4585","LU2106854487.HKD","LU0053666078.USD","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625942915","title":"MAIA Biotechnology secures funding for clinical trial of ateganosine","url":"https://stock-news.laohu8.com/highlight/detail?id=2625942915","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625942915?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:31","pubTimestamp":1775655075,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) announced that net proceeds from its $33M public offering of common stock in March are expected to fully fund the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-secures-funding-for-clinical-trial-of-ateganosine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-secures-funding-for-clinical-trial-of-ateganosine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625494107","title":"Maia Biotechnology says $33 million stock offering fully funds Phase 3 NSCLC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494107","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625494107?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:02","pubTimestamp":1775653369,"startTime":"0","endTime":"0","summary":"Maia Biotechnology raised USD 33 million in a March 2026 public offering of common stock.Net proceeds expected to fully fund pivotal Phase 3 THIO-104 trial of ateganosine in third-line NSCLC through completion.Management flagged interim Phase 3 data expected next year as potential basis for talks with FDA on early full commercial approval in third-line NSCLC.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL47wB7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4588","SG9999014005.SGD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B3QW5Z07.USD","MAIA","BK4139","IE00BN0W2W23.USD","BK4585","BK4112","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625626947","title":"MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2625626947","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625626947?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:00","pubTimestamp":1775653200,"startTime":"0","endTime":"0","summary":"Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probabili","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3270148/0/en/MAIA-Biotechnology-Expects-Recent-33-Million-Capital-Raise-to-Fully-Fund-Ongoing-Pivotal-Phase-3-Trial-of-Novel-Telomere-Targeting-Anticancer-Therapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","L","LU2487616109.SGD","BK4139","CPI","LU0053666078.USD","BK4107","BK4585","LU0210528500.USD","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953032","title":"Maia Biotechnology announces annual shareholder meeting in virtual format","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953032?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:03","pubTimestamp":1775566994,"startTime":"0","endTime":"0","summary":"Maia Biotechnology will hold its annual meeting of stockholders May 21, 2026 in virtual format.Shareholders will vote on election of Class I directors Louie Ngar Yee, Steven Chaouki.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL6Knkh4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624802776","title":"MAIA Biotechnology Awards Executive Bonuses After Successful Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624802776","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624802776?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:43","pubTimestamp":1775166224,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has provided an announcement. On March 27, 2026, MAIA Biotechnology, Inc.’s Board of Directors approved one-ti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-awards-executive-bonuses-after-successful-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-awards-executive-bonuses-after-successful-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624268252","title":"Maia Biotechnology CEO receives one-time $0.3 million bonus tied to capital raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2624268252","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624268252?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:17","pubTimestamp":1775161071,"startTime":"0","endTime":"0","summary":"Maia Biotechnology authorized one-time bonus payments tied to its recent capital raise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL5KMTRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624551595","title":"MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2624551595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624551595?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:29","pubTimestamp":1774992587,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has issued an update. On March 31, 2026, MAIA Biotechnology reported that eight patients in its ongoing Phase ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-highlights-promising-phase-2-nsclc-survival-outcomes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-highlights-promising-phase-2-nsclc-survival-outcomes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623829945","title":"BRIEF-Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2623829945","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623829945?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:26","pubTimestamp":1774963569,"startTime":"0","endTime":"0","summary":"BRIEF-Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung CancerMarch 31 (Reuters) - Maia Biotechnology Inc MAIA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA5BZTJR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622225698","title":"MAIA Showcases THIO-101 NSCLC Data at ELCC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622225698","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622225698?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:16","pubTimestamp":1774617393,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has provided an announcement. MAIA Biotechnology presented a scientific poster titled “Sustained Response and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-showcases-thio-101-nsclc-data-at-elcc-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-showcases-thio-101-nsclc-data-at-elcc-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621080617","title":"MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621080617","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621080617?lang=en_us&edition=fundamental","pubTime":"2026-03-24 06:11","pubTimestamp":1774303872,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 33.33 percent increase over losses of $(0.12) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51421811/maia-biotechnology-q4-eps-0-08-beats-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061117","title":"Maia Biotechnology FY 2025 net loss was USD 22.4 million as R&D expenses rose 45% to USD 14.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061117","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061117?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:03","pubTimestamp":1774271008,"startTime":"0","endTime":"0","summary":"Maia Biotechnology published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 22.4 million.Operating costs and expenses rose 43% to USD 24.3 million, including R&D expense up 45% to USD 14.5 million and G&A expense up 40% to USD 9.7 million.R&D growth was driven mainly by higher scientific pre-clinical research and clinical trial costs, while G&A increased primarily due to higher investor relations expense, stock-based compensation, and professional fees.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Secur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLYMFqR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617560989","title":"MAIA Biotechnology Completes $30 Million Public Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2617560989","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617560989?lang=en_us&edition=fundamental","pubTime":"2026-03-05 07:36","pubTimestamp":1772667409,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology, Inc. ( ($MAIA) ) has shared an update. On March 2, 2026, MAIA Biotechnology, Inc. entered into an underwriting agreement with K...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-completes-30-million-public-stock-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maia-biotechnology-completes-30-million-public-stock-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617627525","title":"BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617627525","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617627525?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:41","pubTimestamp":1772664118,"startTime":"0","endTime":"0","summary":"BRIEF-Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC FilingMarch 4  - SEC Filing:MAIA BIOTECHNOLOGY INC - ON MARCH 2, CO ENTERS UNDERWRITING AGREEMENT WITH KONIK CAPITAL PARTNERS ON MARCH 2, 2026 - SEC FILINGMAIA BIOTECHNOLOGY INC - TO ISSUE 20,000,000 SHARES OF COMMON STOCK IN PUBLIC OFFERING - SEC FILINGSource text: [ID:n0001493152-26-008897]Further company coverage: MAIA.A ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS2BM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617625355","title":"Maia Biotechnology Inc - to Issue 20,000,000 Shares of Common Stock in Public Offering - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617625355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617625355?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:23","pubTimestamp":1772663005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS2BM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617539562","title":"Maia Biotechnology Inc - on March 2, Co Enters Underwriting Agreement With Konik Capital Partners on March 2, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617539562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617539562?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:23","pubTimestamp":1772663005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS2BM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569689","title":"MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569689","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569689?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:00","pubTimestamp":1772658000,"startTime":"0","endTime":"0","summary":"Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March  04, 2026  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249706/0/en/MAIA-Biotechnology-Announces-Closing-of-30-Million-Underwritten-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616934666","title":"BUZZ-MAIA Biotechnology plunges after $30 million share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2616934666","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616934666?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:38","pubTimestamp":1772534337,"startTime":"0","endTime":"0","summary":"BUZZ-MAIA Biotechnology plunges after $30 million share sale** Drug developer MAIA Biotechnology's MAIA.A shares plunge 29% to $1.47 premarket** MAIA late on Monday announced pricing of $30 million public offering** Co sold 20 million shares at $1.50 apiece, a 27.5% discount to stock's last close     ** Offering led by healthcare-dedicated investors alongside existing shareholders - MAIA ** Proceeds will be used to conduct clinical trials and for working capital, general purposes** Konik Capital Partners was sole book-running manager for offering** MAIA had 38.7 million outstanding shares as of March 2, according to offering prospectus** Lone analyst covering MAIA rates it \"buy\" and has $12.14 PT - data compiled by LSEG** As of last close, MAIA stock up 35.3% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL4N3ZQ1F8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"BUZZ-MAIA Biotechnology plunges after $30 million share sale","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616534645","title":"MAIA Biotechnology 20M share Spot Secondary priced at $1.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2616534645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616534645?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:20","pubTimestamp":1772533212,"startTime":"0","endTime":"0","summary":"acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-20m-share-spot-secondary-priced-at-1-50-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-20m-share-spot-secondary-priced-at-1-50-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAIA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616233364","title":"MAIA Biotechnology announces common stock offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2616233364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616233364?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:06","pubTimestamp":1772489216,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology (MAIA) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stoc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-announces-common-stock-offering-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maia-biotechnology-announces-common-stock-offering-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.MAIABiotech.com","stockEarnings":[{"period":"1week","weight":-0.053},{"period":"1month","weight":-0.0458},{"period":"3month","weight":-0.5504},{"period":"6month","weight":-0.0458},{"period":"1year","weight":-0.328},{"period":"ytd","weight":-0.183}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.1224},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0469},{"period":"1year","weight":0.292},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.285723},{"month":2,"riseRate":0,"avgChangeRate":-0.06082},{"month":3,"riseRate":0.25,"avgChangeRate":-0.026788},{"month":4,"riseRate":0.5,"avgChangeRate":0.116267},{"month":5,"riseRate":0.666667,"avgChangeRate":0.134126},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.131471},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058081},{"month":8,"riseRate":0,"avgChangeRate":-0.148704},{"month":9,"riseRate":0.25,"avgChangeRate":0.000086},{"month":10,"riseRate":0.25,"avgChangeRate":-0.039628},{"month":11,"riseRate":0.25,"avgChangeRate":-0.189158},{"month":12,"riseRate":0.5,"avgChangeRate":0.077797}],"exchange":"AMEX","name":"MAIA Biotechnology Inc.","nameEN":"MAIA Biotechnology Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MAIA Biotechnology Inc.,MAIA,MAIA Biotechnology Inc.股票,MAIA Biotechnology Inc.股票老虎,MAIA Biotechnology Inc.股票老虎国际,MAIA Biotechnology Inc.行情,MAIA Biotechnology Inc.股票行情,MAIA Biotechnology Inc.股价,MAIA Biotechnology Inc.股市,MAIA Biotechnology Inc.股票价格,MAIA Biotechnology Inc.股票交易,MAIA Biotechnology Inc.股票购买,MAIA Biotechnology Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MAIA Biotechnology Inc.(MAIA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MAIA Biotechnology Inc.(MAIA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction